KR100325268B1 - Process for producing asiatic acid - Google Patents

Process for producing asiatic acid Download PDF

Info

Publication number
KR100325268B1
KR100325268B1 KR1019940032698A KR19940032698A KR100325268B1 KR 100325268 B1 KR100325268 B1 KR 100325268B1 KR 1019940032698 A KR1019940032698 A KR 1019940032698A KR 19940032698 A KR19940032698 A KR 19940032698A KR 100325268 B1 KR100325268 B1 KR 100325268B1
Authority
KR
South Korea
Prior art keywords
formula
compound
acid
compound represented
producing
Prior art date
Application number
KR1019940032698A
Other languages
Korean (ko)
Other versions
KR960022436A (en
Inventor
주상섭
김희두
정영훈
서성기
남태규
한덕희
박재호
심필종
Original Assignee
동국제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 동국제약 주식회사 filed Critical 동국제약 주식회사
Priority to KR1019940032698A priority Critical patent/KR100325268B1/en
Publication of KR960022436A publication Critical patent/KR960022436A/en
Application granted granted Critical
Publication of KR100325268B1 publication Critical patent/KR100325268B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/02Saturated compounds containing hydroxy or O-metal groups
    • C07C62/06Saturated compounds containing hydroxy or O-metal groups polycyclic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE: Provided is an asiatic acid used as an agent for curing trauma, which is produced by using a madecassic acid, obtained from Centella asiatica, as a starting material. CONSTITUTION: The asiatic acid represented by the formula 9 is produced by treating a compound represented by the formula 8 with lithium iodide and hydrolyzing ester at 28-position, wherein the compound represented by the formula 8 is obtained by hydrolyzing a compound represented by the formula 7 under the acidic condition and removing ketal protecting groups at 2- and 3-position. The compound represented by the formula 7 is produced by treating a compound represented by the formula 5 with AIBN and tributyl tin hydride and removing a substituted hydroxy group at 6-position to obtain a compound represented by the formula 6 and then removing an acetyl protecting group at 2-position with potassium carbonate, wherein the compound represented by the formula 5 is produced by using the madecassic acid as a starting material.

Description

아시아트산의 제조방법How to prepare Asian acid

본 발명은 아시아트산의 제조방법에 관한 것으로, 더욱 자세하게는 천연에서 유래하는 마데카스산을 출발물질로 하여 아시아트산을 제조하는 방법에 관한 것이다.The present invention relates to a method for producing asiatic acid, and more particularly, to a method for producing asiatic acid using a natural madecassic acid as a starting material.

하기식으로 표시되는 아시아트산은 그의 3당류인 아시아티코사이드 및 마데카스산과 같이 센텔라 아시아티카(Centella asiatica)에서 추출되는 물질로서 1941년 본템스등에 의해 최초로 분리되고 [J.E.Bontems, Bull. Sci. Pharmacol.,49, 186-91(1941)], 폴론스키 등에 의해 구조가 결정되었다[J. Polonsky, Compt, Rend., 232, 1878-80(1951); J. Polonsky, Bull Soc. Chim., 173-80(1953)].Asiatic acid represented by the following formula is a substance extracted from Centella asiatica, such as its trisaccharides Asiaticoside and Madecassic acid, and was first isolated by Bontems et al. In 1941 [J.E.Bontems, Bull. Sci. Pharmacol., 49, 186-91 (1941)], Polonsky et al. [J. Polonsky, Compt, Rend., 232, 1878-80 (1951); J. Polonsky, Bull Soc. Chim., 173-80 (1953).

아시아트산 및 아시아티코사이드를 포함한 센텔라 아시아티카의 추출물들은 오래전부터 피부 상처나 만성 궤양등의 치료에 사용되어 왔었고 결핵이나 나병에의한 피부 변형 치료에도 사용되었는데[P. Boiteau, A. Buzas, E. Lederer and J. Polonsky, Bull. Soc. Chim., 31, 46-51(1949)], 이들 물질들의 피부 상처치료의 약리 작용기전은 말피기(Malpighean) 층의 세포를 활성화시키고 케라틴화를 유발시킴으로서 이루어진다고 보고되어 있다[May. Anne, Eur. J. Pharmacol., 4(3), 331-9(1968)].Centella asiatica extracts, including asiatic acid and asiaticosides, have long been used in the treatment of skin wounds and chronic ulcers, and in the treatment of skin transformation caused by tuberculosis or leprosy [P. Boiteau, A. Buzas, E. Lederer and J. Polonsky, Bull. Soc. Chim., 31, 46-51 (1949)], It is reported that the pharmacological mechanism of skin wound healing of these substances is achieved by activating the cells of the Malpighean layer and inducing keratinization [May. Anne, Eur. J. Pharmacol., 4 (3), 331-9 (1968)].

현재시판되고 있는 피부질환치료제인 마데카솔 역시 아시아티코사이드(40%)와 아시아트산 및 마데카스산(60%)의 3가지 화합물의 혼합물로서 그중 아시아트산의 3당류인 아시아티코사이드가 주된 약효를 나타내는 것으로 알려져 있고 아시아트산 자체는 약효가 없는 것으로 보고된 바 있지만 [Kiesswetter, Wien. Med. Woshschr., 114(7), 124-6(1964)], 이는 이들 물질의 체내 흡수과정 차이에 기인한 것으로 실제 약효를 나타내는 물질은 아시아트산 그 자체임을 입증하는 보고[L.F. Chasseaud, B.J. Fry, D.R. Hawkins, J.D. Lewis, T. Taylor ard D. E. Hathway, Arzneim-Forsch, 21(9), 179-84(1971)]도 있어 아시아트산 유도체의 합성 및 그들의 약리 작용에 관심이 모아지고 있다. 그러나 이 아시아트산은 간단한 출발물질로부터 전합성하기에는 합성 단계가 아주 많아 힘들고 경제적으로도 가치가 없기 때문에 문제점으로 지적되어 오고 있다.Madecasol, a currently available treatment for skin diseases, is also a mixture of three compounds of asiaticoside (40%) and asiatic acid and madecassic acid (60%). Asian acid itself has been reported to be ineffective, but [Kiesswetter, Wien. Med. Woshschr., 114 (7), 124-6 (1964)], which is due to differences in the absorption process of these substances in the body, and reports that demonstrate that the substance showing the actual efficacy is asiatic acid itself [L.F. Chasseaud, B.J. Fry, D.R. Hawkins, J.D. Lewis, T. Taylor ard D. E. Hathway, Arzneim-Forsch, 21 (9), 179-84 (1971), are also drawing attention to the synthesis of asiatic derivatives and their pharmacological action. However, this Asian acid has been pointed out as a problem because there are so many synthetic steps that it is difficult to presynthesize from a simple starting material.

이에 본 발명자들은 센텔라 아시아티카에서 아시아트산과 함께 얻어지는 마데카스산을 이용하여 간단한 단계를 거쳐 아시아트산을 합성하는 방법을 최초로 개발하여 본 발명을 완성하였다.The present inventors first developed a method for synthesizing asiatic acid through a simple step using madecassic acid obtained with asiatic acid in Centella asiatica to complete the present invention.

본 발명의 제조 방법을 설명하면 하기와 같다.The manufacturing method of the present invention will be described below.

반응도식Scheme

먼저 구조식(1)의 마데카스산을 2,2-디메톡시프로판을 사용하여 2-위치와 3-위치의 히드록시기를 케탈로 보호하여 화합물(2)를 제조하고 다시 그 화합물을 에스테르 형태인 화합물(3)으로 만든다. 이 화합물(3)의 2-위치의 유리 히드록시기를 아세틸기로 보호하여 구조식(4)의 화합물을 얻는다. 이때 유리 히드록시기는 2-위치와 6-위치의 두군데가 있으나 6-위치의 입체장애로인해 2-위치만 아세틸로 보호된 화합물(4)가 얻어진다. 상기 화합물(4)를 이황화탄소와 요오드화 메틸로 처리하여 구조식(5)의 화합물을 얻고, 이를 AIBN과 수소화 트리부틸주석으로 처리하여 6-위치의 히드록시기가 제거된 화합물(6)를 얻고, 이어서 탄산칼륨으로 2-위치의 아세틸기를 탈보호하여 화합물(7)를 얻고 다시 염산을 사용하여 3∼4위치의 케탈기를 탈보호하고(화합물 8), 28-위치의 에스테르기를 가수분해하여 아시아트산(9)을 함성한다.First, compound (2) was prepared by protecting the 2- and 3-position hydroxy groups with ketal using 2,2-dimethoxypropane, and preparing the compound (2) in ester form. 3) made of The 2-hydroxy free hydroxyl group of this compound (3) is protected by an acetyl group to obtain a compound of formula (4). At this time, the free hydroxy group has two positions, 2-position and 6-position, but compound (4) where only 2-position is protected by acetyl due to the 6-position steric hindrance is obtained. The compound (4) was treated with carbon disulfide and methyl iodide to obtain a compound of formula (5), which was then treated with AIBN and tributyltin hydride to obtain a compound (6) having 6-position removed hydroxy group, followed by carbonic acid. Using potassium to deprotect the 2-position acetyl group to obtain compound (7), and again using hydrochloric acid to deprotect the ketal group at the 3-4 position (compound 8), hydrolyzing the ester group at 28-position to 9) shouts.

이하 실시예로 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail with reference to the following Examples.

실시예 1 : 3,23 - O - 이소프로필리덴 마데카스산의 제조Example 1 Preparation of 3,23-O-Isopropylidene Madecaic Acid

마데카스산(1g)과 p-톨루엔술폰산(50mg)을 디메틸포름아미드 10 ml에 녹이고, 여기에 2,2 - 디메톡시프로판 0.5ml를 가하여 실온에서 12 시간 교반하였다. 반응 혼합액에 5% K2CO3를 가해 중화하고 30분간 교반했다.Madecassic acid (1 g) and p-toluenesulfonic acid (50 mg) were dissolved in 10 ml of dimethylformamide, 0.5 ml of 2,2-dimethoxypropane was added thereto, followed by stirring at room temperature for 12 hours. 5% K 2 CO 3 was added to the reaction mixture, neutralized and stirred for 30 minutes.

용매를 감압하에 증류제거하고, 잔사를 에틸 아세테이트로 추출하여 컬럼 크로마토그래피(디클로로메탄/메탄올 = 30/1)로 정제하여 목적물 0.97g(90%)을 백색 고체로서 얻었다.The solvent was distilled off under reduced pressure, and the residue was extracted with ethyl acetate and purified by column chromatography (dichloromethane / methanol = 30/1) to obtain 0.97 g (90%) of the title compound as a white solid.

실시예 2 : 메틸 3,23 - 0 - 이소프로필리덴마데카세이트의 제조Example 2 Preparation of Methyl 3,23-0 Isopropylidene Madecassate

실시예 1 에서 수득된 화합물(1g)을 에틸 에테르에 용해시키고 CH2N2의 에테르 용액을 가하되 반응 혼합액이 연황색이 될 때까지 적가하고 실온에서 1시간 동안 교반했다. 용매를 감압하에 증류제거하고 잔사를 짧은 컬럼으로 여과하여 백색의 고체 0.98g(96%)을 얻었다.The compound (1 g) obtained in Example 1 was dissolved in ethyl ether and an ether solution of CH 2 N 2 was added, but added dropwise until the reaction mixture became light yellow and stirred at room temperature for 1 hour. The solvent was distilled off under reduced pressure and the residue was filtered through a short column to obtain 0.98 g (96%) of a white solid.

실시예 3Example 3

실시예 2에서 제조된 화합물(3)(1000mg, 1.792mmol)을 무수 디클로로메탄 (10ml)에 녹이고 여기에 피리딘(434㎕, 5.376mmol)과 무소초산(254㎕, 2.688mmol)을 가하고 0℃에서 실온까지 가온하면서 48시간동안 교반했다. 5% 탄산칼륨(2ml)로 반웅혼합액을 처리하고 디클로로메탄을 감압농축하여 제거했다. 얻어진 잔사를 에틸 아세테이트(50ml)로 추출하고, 유기층을 물(5mlx3)과 염수(5mlx3)로 세척하고 무수 황산 마그네슘으로 건조시켰다.Compound (3) (1000 mg, 1.792 mmol) prepared in Example 2 was dissolved in anhydrous dichloromethane (10 ml), and pyridine (434 μl, 5.376 mmol) and acetic anhydride (254 μl, 2.688 mmol) were added thereto at 0 ° C. Stir for 48 hours while warming to room temperature. The reaction mixture was treated with 5% potassium carbonate (2 ml), and dichloromethane was removed by concentration under reduced pressure. The obtained residue was extracted with ethyl acetate (50 ml), and the organic layer was washed with water (5 mlx3) and brine (5 mlx3) and dried over anhydrous magnesium sulfate.

감압농축하여 얻어진 관사를 컬럼 크로마토그래피(에틸 아세테이트/헥산= 1/3)로 정제하여 화합물(4) 892mg(83%)을 백색고체로서 얻었다.The article obtained by concentrating under reduced pressure was purified by column chromatography (ethyl acetate / hexane = 1/3) to obtain 892 mg (83%) of compound (4) as a white solid.

실시예 4Example 4

실시예 3에서 제조된 화합물 4(500mg, 0.833mmol)와 NaH(60% 무기 오일, 166mg, 4.165mmol)에 무수 테트라히드로푸란(10ml)를 가하고 3시간 동안 가열환류했다.Anhydrous tetrahydrofuran (10 ml) was added to Compound 4 (500 mg, 0.833 mmol) and NaH (60% inorganic oil, 166 mg, 4.165 mmol) prepared in Example 3, followed by heating to reflux for 3 hours.

여기에 이황화탄소(5ml)를 가하고 10시간 동안 가열환류했다. 반응 혼합물에 요오드화 메틸(0.5ml)을 가하고 1시간 동안 가열환류했다.Carbon disulfide (5 ml) was added thereto and heated to reflux for 10 hours. Methyl iodide (0.5 ml) was added to the reaction mixture, and the mixture was heated to reflux for 1 hour.

반응혼합액을 물(1ml)로 처리하고 THF를 감압농축하여 제거했다.The reaction mixture was treated with water (1 ml) and THF was concentrated under reduced pressure to remove.

얻어진 잔사를 에틸 아세테이트(50ml)로 추출하고 유기층을 물(5mlx3)과 염수(5mlx3)로 세척했다. 무수 황산 마그네슘으로 건조하고 감압농축하여 얻어진 잔사를 컬럼 크로마토그래피(에틸아세테이트/헥산 = 1/6)로 정제하여 화합물(5) 406mg(71%)을 백색고체로서 얻었다.The obtained residue was extracted with ethyl acetate (50 ml) and the organic layer was washed with water (5 ml × 3) and brine (5 ml × 3). The residue obtained by drying over anhydrous magnesium sulfate and concentrated under reduced pressure was purified by column chromatography (ethyl acetate / hexane = 1/6) to obtain 406 mg (71%) of compound (5) as a white solid.

실시예 5Example 5

실시예 4에서 수득된 화합물 5(284mg, 0.41lmmol)과 촉매량의 AIBN에 무수 벤젠(5ml)을 가해 녹이고, 수소화트리부틸주석(228㎕, 0.823mmol)을 가하고 1시간동안 가열환류했다.Anhydrous benzene (5 ml) was added to Compound 5 (284 mg, 0.41 lmmol) obtained in Example 4 and the catalytic amount of AIBN to dissolve. Tributyltin hydride (228 µl, 0.823 mmol) was added thereto, and the mixture was heated and refluxed for 1 hour.

벤젠을 감압농축하여 제거하고 잔사를 컬럼 크로마토그래피(에틸 아세테이트/헥산 = 1/5)로 정제하여 화합물(6) 222mg(93%)을 백색고체로서 얻었다.Benzene was concentrated under reduced pressure, and the residue was purified by column chromatography (ethyl acetate / hexane = 1/5) to give 222 mg (93%) of the compound (6) as a white solid.

실시예 6Example 6

실시예 5에서 수득된 화합물 6(34mg, 0.0582mmol)와 탄산칼륨(16mg, 0.115mmol)에 메탄올과 물의 혼합용매(메탄올:물 = 10:1, 3ml)를 가해 녹이고 실온에서 2시간 동안 교반했다.To a compound 6 (34 mg, 0.0582 mmol) and potassium carbonate (16 mg, 0.115 mmol) obtained in Example 5, a mixed solvent of methanol and water (methanol: water = 10: 1, 3 ml) was added thereto to dissolve and stirred at room temperature for 2 hours. .

메탄올과 물을 감압농축하여 제거하고 잔사를 컬럼크로마토그래피(에틸아세테이트:헥산 = 1:5)로 정제하여 화합물(7) 25mg(80%)를 백색고체로서 얻었다.Methanol and water were concentrated under reduced pressure, and the residue was purified by column chromatography (ethyl acetate: hexane = 1: 5) to obtain 25 mg (80%) of the compound (7) as a white solid.

실시예 7Example 7

실시예 6에서 제조된 화합물 7(60mg, 0.110mmol)에 THF(3ml)와 IN-HCl(0.3ml)를 가하고 실온에서 2시간 동안 교반했다.To compound 7 (60 mg, 0.110 mmol) prepared in Example 6, THF (3 ml) and IN-HCl (0.3 ml) were added, and the mixture was stirred at room temperature for 2 hours.

반응 혼합액을 감압농축하고 얻어진 잔사를 컬럼 크로마토그래피(헥산:에틸아세테이트 = 2:3)로 정제하여 화합물(8) 53mg(95%)을 백색고체로서 얻었다.The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by column chromatography (hexane: ethyl acetate = 2: 3) to obtain 53 mg (95%) of the compound (8) as a white solid.

실시예 8 : 아시아트산(9)의 제조Example 8 Preparation of Asian Acid (9)

메틸 아시아테이트(8)(500mg)와 LiI·3H2O (570mg)의 혼합물에 2,4,6 - 콜리딘(10ml)을 가하고 10시간 동안 가열환류했다. 반응 혼함물온 감압농축시켜 콜리딘을 제거하고 잔사를 컬럼 크로마토그래피 (디클로로메탄/메탄올 = 20/1)로 정제하여 아시아트산(9) 366mg(75%)를 얻었다.2,4,6-collidine (10 ml) was added to a mixture of methyl asiaate (8) (500 mg) and LiI.3H 2 O (570 mg) and heated to reflux for 10 hours. The reaction mixture was concentrated under reduced pressure to remove collidine, and the residue was purified by column chromatography (dichloromethane / methanol = 20/1) to give 366 mg (75%) of asiatic acid (9).

Claims (3)

하기 식 7의 화합물을 산조건하에서 가수분해시켜 2-위치와 3-위치의 케탈 보호기를 제거하여 하기 식 8의 화합물을 수득하고, 이를 요오드화 리튬으로 처리하여 28-위치의 에스테르를 가수분해시킴을 특징으로 하는 하기 식 9의 아시아트산의 제조방법.The compound of formula 7 was hydrolyzed under acid conditions to remove the ketal protecting groups in 2-position and 3-position to obtain the compound of formula 8, which was treated with lithium iodide to hydrolyze the ester at 28-position. A process for producing the aspartic acid of formula 9 below. 제1항에 있어서, 상기 식 7의 화합물은 하기 식 5의 화합물을 AIBN과 수소화트리부틸주석으로 처리하여 6-위치의 치환된 히드록시기를 제거하여 하기식 6의 화합물을 얻은 다음, 탄산칼륨으로 2-위치의 아세틸 보호기를 제거함으로써 제조되는 것을 특징으로하는 아시아트산의 제조방법.According to claim 1, wherein the compound of Formula 7 is treated with AIBN and tributyltin hydride compound of formula 5 to remove the substituted hydroxy group in the 6-position to obtain a compound of formula 6, and then to 2 A process for producing aspartic acid, characterized in that it is prepared by removing the acetyl protecting group in position. 제2항에 있어서,상기 식 5의 화합물은 하기 식 1의 마데카스산을 출발물질로 하고 2,2-디메톡시프로판을 사용하여 3-위치와 4-위치의 유리 히드록시기가 케탈 형태로 보호된 하기식 2의 화합물을 얻고, CH2N2의 에테르 용액을 가하여 식 2 화합물의 메틸 에스테르 형태인 하기식 3 화합물로 변환시키고, 수득된 식 3의 화합물에 아세트산 무수물을 가하여 2-위치의 유리 히드록시가 보호된 형태인 하기식 4의 화합물로 전환시킨 다음, 식 4의 화합물을 이황화탄소와 요오드화 메틸로 처리하여 5-위치의 유리 히드록시기를 (메틸티오)티오카르보닐기로 보호함으로써 제조되는것을 특징으로 하는 아시아트산의 제조방법.According to claim 2, The compound of Formula 5 is a starting material and the free hydroxyl group of the 3-position and 4-position in the ketal form using a madecaic acid of the following formula 1 and 2,2-dimethoxypropane The compound of formula 2 was obtained, an ether solution of CH 2 N 2 was added to convert into a compound of formula 3, which is a methyl ester form of formula 2, and acetic anhydride was added to the compound of formula 3 to obtain a free hydroxide in 2-position. It is prepared by converting a compound of formula 4, which is in hydroxy protected form, and then treating the compound of formula 4 with carbon disulfide and methyl iodide to protect the 5-hydroxy free hydroxy group with a (methylthio) thiocarbonyl group. A method for producing asiatic acid.
KR1019940032698A 1994-12-03 1994-12-03 Process for producing asiatic acid KR100325268B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940032698A KR100325268B1 (en) 1994-12-03 1994-12-03 Process for producing asiatic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940032698A KR100325268B1 (en) 1994-12-03 1994-12-03 Process for producing asiatic acid

Publications (2)

Publication Number Publication Date
KR960022436A KR960022436A (en) 1996-07-18
KR100325268B1 true KR100325268B1 (en) 2002-07-27

Family

ID=37478178

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940032698A KR100325268B1 (en) 1994-12-03 1994-12-03 Process for producing asiatic acid

Country Status (1)

Country Link
KR (1) KR100325268B1 (en)

Also Published As

Publication number Publication date
KR960022436A (en) 1996-07-18

Similar Documents

Publication Publication Date Title
Takatsuto et al. Stereoselective synthesis of plant growth-prompting steroids, brassinolide, castasterone, typhasterol, and their 28-nor analogues
FR2727678A1 (en) ASIAN ACID DERIVATIVES, THEIR MANUFACTURING PROCESS AND DERMATOLOGICAL AGENTS CONTAINING THEM
Pereda-Miranda et al. Triterpenoids and flavonoids from Hyptis albida
Paquette et al. Stereocontrolled construction of an ingenol prototype having a complete array of oxygenated and unsaturated centers
Sarett et al. Approaches to the Total Synthesis of Adrenal Steroids. VII. A New Method for the Attachment of Ring D. Part A
KR100325268B1 (en) Process for producing asiatic acid
DE2426528C3 (en) Process for the production of 25-hydroxycholesterol and 20 (S) -25-hydroxycholesterol and its derivatives
Hayashi et al. Reaction and interconversion of norditerpenoid dilactones, biologically active principles isolated from Podocarpus plants
Seiber et al. Three new cardenolides from the milkweeds Asclepias eriocarpa and A. labriformis
AT390252B (en) METHOD FOR PRODUCING 6-DEOXYANTHRACYCLINONES
Díaz et al. Sesquiterpene lactones and other constituents of Mikania rimachii and Mikania microptera
Dixon et al. Preparation of an analogue of orbicuside A, an unusual cardiac glycoside
Xing-Xiang et al. Total synthesis of arteannuin and deoxyarteannuin
SU439973A1 (en) Method for preparing methyl 19-norprogesterone derivative
HAYASHI et al. Studies on the constituents of Asclepiadaceae Plants. XXXIV. Chemistry of sarcostin
DE1518666A1 (en) Process for the manufacture of 13,14 seco steroids
Furukawa et al. Carolenin and carolenalin, two new guaianolides in Helenium autumnale from North Carolina
GB2036030A (en) Process for the manufacture of 1 3 -dihydroxy steroids
Sanchez et al. Short, high-yield syntheses of (.+-.)-curcuhydroquinone and (.+-.)-curcuquinone
Harnik et al. Synthesis of 19-hydroxyaldosterone and the 3β-hydroxy-5-ene analog of aldosterone, active mineralocorticoids
Hajos et al. Synthesis and Stereochemistry of Hydrophenanthrenes. III. 1 The Reaction of 1, 3-Dicyclohexyl-1-(1, 2, 3, 9, 10, 10aβ-hexahydro-7-methoxy-2α-phenanthrylc arbonyl) urea with Sodium Alkoxides
EP0971873A1 (en) Asiatic acid derivatives and medicines for treating wounds, which contains the same
US3365474A (en) Polyhydroxypregn-7-enes and processes for their preparation
US4097477A (en) Steroid compounds and processes thereof
Nampalli et al. PBr3-DMF Assisted Elimination of a Highly Hindered Diallylic Tertiary Alcohol in a Bicyclic System: Synthesis of a Key Intermediate Useful for the Total Synthesis of Forskolin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee